Damora Therapeutics, Inc. (DMRA) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.4x

Market Cap

$1.86B

MomentumView details →

1D Return

+7.36%

YTD Return

+22.47%

RSI (14)

41.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.4x

Market Cap

$1.86B

RSI (14)

41.7

MomentumView details →

1D Return

+7.36%

YTD Return

+22.47%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−50.93%

ROA (TTM)

−48.35%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−$0.39

EPS Surprise

5.79%

Beats (12Q)

1/12

Next Q EPS Est

−$0.47

Avg Surprise (4Q)

5.79%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

19.73x

Quick Ratio

19.73x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−262.83M

Op. CF (TTM)

—

Next earningsNov 5, 2026 →

Latest newsMore news →

No recent news for DMRA.

Similar companies

Immunocore Holdings plcIMCR 金迪克688670.SH Mind Medicine (MindMed) Inc.MNMD Galapagos N.V. Sponsored ADRLKFT Galapagos N.V.GLPG Syndax Pharmaceuticals, Inc.SNDX Find similar companies →

Latest newsMore news →

No recent news for DMRA.